mezlocillin has been researched along with aztreonam in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parry, MF | 1 |
| Ramirez-Ronda, CH; Rivera-Vazquez, CR; Rodriguez, JR; Saavedra, S | 1 |
| Busuttil, RW; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ | 1 |
| Alivisatos, MR; Bollinger, MR; Greenberg, RN | 1 |
| Danko, LS; Greenberg, RN; Meade, DW | 1 |
| Brade, V; Hunfeld, KP; Kekoukh, E; Kraiczy, P; Weigand, J; Wichelhaus, TA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Anderson, KC; Kellogg, GE; Sarkar, A | 1 |
1 review(s) available for mezlocillin and aztreonam
| Article | Year |
|---|---|
Ureidopenicillins, aztreonam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy.
Topics: Aminoglycosides; Ampicillin; Azlocillin; Aztreonam; Bacteria; Bacterial Infections; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Humans; Mezlocillin; Piperacillin; Pseudomonas aeruginosa; Thienamycins | 1986 |
1 trial(s) available for mezlocillin and aztreonam
| Article | Year |
|---|---|
A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Aztreonam; Bacterial Infections; Clindamycin; Clinical Trials as Topic; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Male; Mezlocillin; Middle Aged; Pneumonia; Random Allocation; Tobramycin | 1989 |
9 other study(ies) available for mezlocillin and aztreonam
| Article | Year |
|---|---|
Aztreonam susceptibility testing. A retrospective analysis.
Topics: Ampicillin; Aztreonam; Bacteria; Cefotaxime; Ceftazidime; Gentamicins; Mezlocillin; Microbial Sensitivity Tests | 1990 |
In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azlocillin; Aztreonam; Cefoperazone; Ceftazidime; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Mezlocillin; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Ticarcillin | 1986 |
Comparison of the synergic activity of aztreonam or tobramycin plus piperacillin or mezlocillin.
Topics: Aztreonam; Drug Synergism; Drug Therapy, Combination; Humans; Mezlocillin; Microbial Sensitivity Tests; Piperacillin; Tobramycin | 1993 |
In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi.
Topics: Anti-Bacterial Agents; Aztreonam; Borrelia burgdorferi Group; Drug Resistance, Microbial; Fusidic Acid; Humans; Meropenem; Mezlocillin; Microbial Sensitivity Tests; Monobactams; Penicillins; Ribostamycin; Teicoplanin; Thienamycins; Vancomycin | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics | 2012 |